“Axial spondyloarthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered • Global coverage
Axial spondyloarthritis Understanding
Axial spondyloarthritis: Overview The term axial spondyloarthritis covers both the early inflammatory phase of the disease in which there is no structural damage in the sacroiliac joints (non-radiographic disease) and the later stages in which structural damage is visible on X?ray scans of the sacroiliac joints as erosions, sclerosis or bony bridges (radiographic disease; also known as ankylosing spondylitis). In addition, patients with radiographic axial spondyloarthritis might have abnormalities in X?ray scans of the spine, the most important one being syndesmophytes (vertical bony growth between the corners of two vertebral bodies).
Axial spondyloarthritis is divided into non-radiographic and radiographic disease (also known as ankylosing spondylitis) according to the presence of radiographic changes of the sacroiliac joints. Changes in the spine evident on X-ray can occur in radiographic axial spondyloarthritis, but spinal radiographs can also be normal.
"Axial spondyloarthritis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Axial spondyloarthritis pipeline landscape is provided which includes the disease overview and Axial spondyloarthritis treatment guidelines. The assessment part of the report embraces, in depth Axial spondyloarthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Axial spondyloarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights • The companies and academics are working to assess challenges and seek opportunities that could influence Axial spondyloarthritis R&D. The therapies under development are focused on novel approaches to treat/improve Axial spondyloarthritis.
Axial spondyloarthritis Emerging Drugs Chapters This segment of the Axial spondyloarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Axial spondyloarthritis Emerging Drugs • Tofacitinib: Pfizer
Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs.
• Bimekizumab: UCB Biopharma
Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F. Bimekizumab binds to and neutralizes IL-17A and IL-17F, preventing their interactions with the IL-17 receptors expressed on keratinocytes, fibroblast-like synoviocytes, endothelial cells, chondrocytes and osteoblasts. The drug is currently in phase 3 of development stage for the treatment of Axial spondylarthritis.
• Tildrakizumab: Sun Pharma Global
Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of the interleukin-23 (IL-23) cytokine and inhibits its interaction with the IL-23 receptor. IL-23 plays a critical role in modulating inflammatory and immune responses. In March 2018, the biological treatment tildrakizumab (Ilumya) received US Food and Drug Administration (FDA) approval for the treatment of moderate-to-severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy.
Further product details are provided in the report……..
Axial spondyloarthritis: Therapeutic Assessment This segment of the report provides insights about the different Axial spondyloarthritis drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Axial spondyloarthritis
There are approx. 30+ key companies which are developing the therapies for Axial spondyloarthritis. The companies which have their Axial spondyloarthritis drug candidates in the most advanced stage, i.e. phase III include, UCB Biopharma.
This report covers around 30+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Axial spondyloarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Recombinant fusion proteins
• Small molecule
• Peptide vaccine
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Axial spondyloarthritis: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Axial spondyloarthritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Axial spondyloarthritis drugs.
Current Treatment Scenario and Emerging Therapies: • How many companies are developing Axial spondyloarthritis drugs?
• How many Axial spondyloarthritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Axial spondyloarthritis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Axial spondyloarthritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Axial spondyloarthritis and their status?
• What are the key designations that have been granted to the emerging drugs?
“Neutropenia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in Neutropenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and...
“Sialorrhoea – Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Sialorrhoea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule...
“Protein 50S ribosomal subunit inhibitors– Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Protein 50S ribosomal subunit inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment...
This report was created for global strategic planners who cannot be content with traditional methods of segmenting world markets. With the advent of a "borderless world", cities become a more important criteria in prioritizing markets, as opposed to regions, continents, or countries. This report covers the top 2,000 cities in over 200 countries....
175 pages •
By The Business Research Company
• Jun 2021
Major players in the enzymes market are Sanofi, AbbVie Inc., Alexion Pharmaceuticals Inc, Horizon Pharma, Allergan plc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences, and Roche Holdings AG The global enzymes market is expected to grow from $7.81 billion in 2020 to $8.9 billion in 2021 at a compound annual growth rate (CAGR)...
Global Cell Isolation Market By Product (Consumables and Instruments), By Cell Type (Human Cells and Animal Cells), By Source (Bone Marrow, Cord Blood/Embryonic Stem Cells, Adipose Tissue), By Technique (Centrifugation-Based Cell Isolation, Surface Marker-Based Cell Isolation, Filtration-Based Cell Isolation), By Application (Biomolecule...
Global Hospital Care Partnering 2014 to 2021 provides the full collection of Hospital Care disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Hospital Care partnering deals Financial deal terms for headline, upfront and royalty by stage of development Hospital...
The Formulation Development Outsourcing market was valued at approximately USD 8,055 million in 2020 and is expected to witness a revenue of USD 12,650 million in 2026, with a CAGR of 7.2% over the forecast period. The rapidly evolving threat of COVID-19 is impacting lives, communities, businesses, and industries around the world. The...
306 pages •
By Global Industry Analysts
• May 2021
Global Cell Harvesting Market to Reach $359.2 Million by 2026
Cell harvesting is a next-generation technique that involves collection of stem cells from the culture media for R&D and therapeutic applications. Growth in the global market is spurred by of increasing investments...
With advances in antibody-based therapies, bispecific antibodies (bsAbs) have gained momentum in the last few years after the regulatory approvals of Amgen’s blinatumomab (Blincyto®) and Chugai’s Hemlibra for Hemophilia A. The key advantage of bsAbs lies in their ability to bind two different epitopes or antigens, thereby overcoming the limitations...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.